Yaoming Haide, a subsidiary of YaoMing biology, signed a long-term production and supply contract with the global vaccine giant

Wuxi biology, the world's leading open biopharmaceutical technology platform company, 2269 HK) yesterday announced that its subsidiary, yaominghead, which is engaged in vaccine contract customized R & D and production (cdmo) services, has entered into a strategic partnership with a global vaccine giant, signing a 20-year vaccine production and supply contract, which will build a new vaccine production base in Ireland to serve the global market, with a total amount of about US $3 billion According to the contract, yaominghead has set out to build a new industrial production and supply base in Ireland that integrates vaccine stock solution, preparation, process amplification and quality control (QC) laboratory, specializing in the production of innovative vaccines for the customer to supply the global market The production base is expected to be put into operation in 2022 In November 2019, yaominghead announced to invest 240 million US dollars to build production bases such as vaccine stock solution and preparation plants The base will be located in pharming bio Ireland Park, adjacent to the world's leading biopharmaceutical "future factory" production base under construction by pharming bio, which is expected to be put into commercial production in 2021 Yaoming Hyde is a joint venture established by Yaoming biology and Shanghai based Haili Biology (Stock Code: 603718 SH) It is committed to building a leading integrated capability and technology platform in the global vaccine industry, providing cdmo services and enabling global vaccine industry research, development and production "This strategic cooperation has created a new mode of cooperation in the vaccine industry, which is of historic significance to the pharmaceutical biotechnology, pharmaceutical Hyde and even the global vaccine industry Due to the high complexity of production process, various analytical methods and strict regulatory standards, vaccine production is very difficult Process quality control in the production process is also crucial to ensure product quality This time, we have reached a strategic partnership with the global vaccine giant to produce an innovative vaccine and supply it to the global market, which further demonstrates the leading technological advantages of YaoMing biology and Yaoming Hyde and the global high standard quality system " Dr Chen Zhisheng, CEO and chairman of YaoMing Hyde, said, "the vaccine cdmo business is one of the new growth points of the development of YaoMing biology, and the launch of the project will further promote the vaccine business to further help the company to maintain high-speed growth Together with Yaoming Hyde, Yaoming biology will continue to enable partners to produce high-quality therapeutic protein drugs and vaccine products through a sound and strong global supply chain network, so as to benefit global patients and protect human health " Adorable adorable